LUTZ, Fla.--(BUSINESS WIRE)--CytoDyn Inc., (“the Company”) (OTC QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency virus and other antibody applications, announced today that the board of directors of the Company unanimously approved the addition and election of Anthony D. Caracciolo to serve as a member of the Company’s board of directors.
